Clotinab (abciximab) / ISU Abxis - LARVOL DELTA

ACUTE THROMBOTIC LEFT MAIN CORONARY OSTIAL OCCLUSION- SAILING THROUGH THE STORM (ACC 2026) - "After serial balloon dilatations, TIMI-1 flow was achieved which subsequently improved to TIMI-2 flow following administration of intracoronary abciximab, adenosine and adrenaline... In patients with ST elevation myocardial infarction with cardiogenic shock, circulatory support with Impella is crucial in improving outcomes before urgent revascularization. Nevertheless, the absence of these (in resource constrained settings) should not deter us from urgent coronary revascularization."

Cardiovascular • Myocardial Infarction • Renal Disease • Respiratory Diseases • Thrombosis

COMPARISION OF ROUTINE VASCULAR BED PREPARATION VERSUS NEED BASED VASCULAR BED PREPARATION IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (ACC 2026) - "Vasodilators included abciximab, adenosine, diltiazem, adrenaline, and nitrate. Despite advances in primary PCI, no-reflow continues to pose a major limitation. Targeted distal pharmacotherapy using the perforated balloon approach provides a practical, efficient, and economical solution to mitigate this complication."

Clinical

Intracoronary versus intravenous Abciximab in patients with STEMI undergoing percutaneous coronary intervention: a systematic review and meta-analysis (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making? (PubMed, Stroke) - "Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial."

Journal • Review • Cardiovascular • Ischemic stroke • Thrombosis

Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. (PubMed, Transfusion) - "PRCFC and LIFC retained critical hemostatic functions of VWF and fibrinogen to support platelet adhesion and aggregation during physiologic shear. PRCFC and LIFC represent a therapeutic option for early treatment of massive hemorrhage."

Journal • Hematological Disorders • Infectious Disease • Thrombosis

Enhancing hemostasis in glanzmann thrombasthenia via protein S inhibition (ASH 2025) - "Acute bleeds are primarily managed withplatelet transfusions, and recombinant factor VIIa is used for refractory cases or perioperative support.HMB-001, a novel bispecific antibody, is under investigation as the first prophylactic therapy for GT.Protein S (PS) is a natural anticoagulant that functions as a cofactor for activated protein C, and tissuefactor pathway inhibitor, and independently regulates the prothrombinase and tenase complexes,thereby reducing thrombin generation...Clot retraction was assessed in healthy donor PRP treated with anti-PS antibody, anti-αIIbβ3 antibody (abciximab), both antibodies, or vehicle... A single PS-siRNA injection in αIIbβ3⁻/⁻ mice prevented overt bleeding at necropsy, unlike PBS-treated controls, which showed visible mucocutaneous and GI bleeding. This correlated with a significantincrease in endogenous thrombin potential (ETP): 774 ± 125 nM in PS-siRNA–treated mice vs. 438 ± 81 nMin PBS controls (n = 2–3), indicating that..."

Gastrointestinal Disorder • Hematological Disorders • Hemophilia • Rare Diseases • PROS1 • TINCR

Mechanobiology of Megakaryocyte-Driven Contraction of Plasma Clots (ASH 2023) - "In addition, contraction of plasma clots by activated iMKs was abrogated by 10μg/ml abciximab, that prevented binding of fibrin(ogen) to integrin a IIbb 3 receptors... We have demonstrated a hitherto unknown ability of individual MKs to shrink fibrin clots and deciphered the cellular mechanisms of contractility of iPSC-derived MKs. The molecular mechanisms of MK-driven fibrin clot shrinkage were shown to be similar or identical to those of activated platelets, involving non-muscle myosin II activity, actin polymerization, and integrin αIIbβ3-fibrin interactions. Our findings provide a novel mechanistic insight into mechanobiology of MKs that may play a role in modulating the properties of hemostatic blood clots and thrombi."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis

Red Blood Cell Aggregation within a Blood Clot Causes Clot Shrinkage (ASH 2024) - "This process was insensitive to the inhibitors of platelet contractility, such as blebbistatin, latrunculin A, and abciximab...This study provides compelling evidence that RBCs play a role in blood clot shrinkage unrelated to platelets, suggesting that aggregating RBCs contribute actively to the blood clot contraction. Physiologically, the RBC-induced clot shrinkage may reinforce the platelet-driven blood clot contraction and/or promote clot compaction when there are few or dysfunctional platelets."

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

OPTIMAL INTRAPROCEDURAL ANTIPLATELET STRATEGY DURING RESCUE STENTING FOR REFRACTORY LARGE VESSEL OCCLUSION: A SUB-STUDY OF THE RESISTANT REGISTRY (WSC 2025) - "Antiplatelet regimens were classified as intravenous (IV-APT) (cangrelor, tirofiban, eptifibatide, abciximab), single oral (aspirin, clopidogrel, ticagrelor), or dual oral therapy. ConclusionsIntraprocedural intravenous antiplatelet therapy was associated with improved procedural success and reduced re-occlusion without a significant impact on hemorrhagic or functional outcomes. These findings support the procedural safety of IV antiplatelets and highlight their potential benefit in optimizing reperfusion outcomes during rescue stenting."

Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents. (PubMed, Blood Vessel Thromb Hemost) - "Platelet accumulation was inhibited by abciximab but not aspirin, whereas coagulation inhibitors (5G9, argatroban, heparin) markedly reduced thrombus formation. These findings support that the Endo-chip laser-injury model incorporates key features of thrombus formation after endothelial injury, and provides a humanized, in vitro, alternative or auxiliary to mouse models for preclinical studies and antithrombotic drug development."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Thrombosis • ANXA5

Role of routine vascular bed preparation in patients undergoing primary percutaneous coronary intervention (ESC-WCC 2025) - "Group A: -Intracoronary vasodilator (abciximab, adenosine, diltiazem, adrenaline, nitrate) via guiding catheter followed by primary PCI. Conclusion- No-reflow is not infrequent following PCI especially in setting of primary PCI. Distal drug delivery through perforated balloon technique is easy, reproducible, less time consuming and cost-effective technique to prevent no reflow."

Clinical • Cardiovascular • Myocardial Infarction • Reperfusion Injury • Thrombosis

Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases. (PubMed, Front Neurol) - "No fatal hemorrhages occurred following abciximab administration. Abciximab was safe and seemed effective for the management of thromboembolic complications during endovascular treatment of intracranial aneurysms, without increasing infarct burden or compromising functional outcomes in affected patients."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling. (PubMed, Sci Rep) - "Drug repurposing and molecular docking suggested abciximab and paclitaxel as potential therapeutic agents targeting CD40, while ivermectin emerged as a strong candidate for LRP1 binding. In conclusion, our integrative bioinformatics frameworks links genomics and transcriptomics with network biology and structural modeling, providing valuable insights into the molecular mechanisms of AAA and potential therapeutic strategies."

Clinical • IO biomarker • Journal • Retrospective data • Cardiovascular • Infectious Disease • CD40 • LRP1

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. (PubMed, Pharmacoepidemiol Drug Saf) - "Our numerical results support the use of SBW in situations where IVs or near-IVs may lead to practical violations of positivity assumptions."

Clinical • Journal

The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab. (PubMed, Cardiol J) - "In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The internal standard, abciximab, used the peptide VQWLQAGK with parent and daughter ions at m/z 471.26 and 590.32, respectively. Matrix effects at low and high QC levels confirmed consistency, with accuracy and precision for atezolizumab and bevacizumab exceeding ICH guidelines. This optimized method offers a valuable tool for pharmacokinetic profiling of atezolizumab and bevacizumab in rat plasma, providing insights for therapeutic monitoring and drug development."

Journal • PK/PD data • Preclinical

Platelet a-tubulin is ubiquitinated and degraded downstream of aIIbß3-mediated outside-in signaling (ISTH 2025) - "Methods Using immunoblot (IB) analysis we performed a time course of PAR-1 activating peptide (T6)-induced platelet aggregation (fibrinogen-mediated), thrombin-induced aggregation (fibrinogen/fibrin-mediated), and thrombin (Thr)-induced aggregation of platelets treated with RGDW peptide or abciximab to inhibit fibrinogen binding (fibrin-mediated delayed wave (DW)) 2...These data suggest a correlation of α-tubulin degradation with outside-in signaling through αIIbβ3 rather than inside-out signaling. This hypothesis was supported by the data in Figure 2C, in which inhibition of fibrinogen binding resulted in a reduction in tubulin degradation Table or Figure Upload"

Targeted Protein Degradation

Coronary artery ectasia presenting as acute coronary syndrome and misinterpreted as coronary artery perforation: Case report. (PubMed, Medicine (Baltimore)) - "Stagnant flow in dilated vessels can cause local dye deposition, which may resemble procedure-induced perforation or dissection, necessitating heightened caution during PCI. Intravascular ultrasound is valuable for accurate assessment of lesions in CAE. Thrombectomy and glycoprotein IIb/IIIa inhibitors would be considered to manage high thrombus burden. Due to its diverse clinical presentations, CAE requires an individualized strategy, and can also be treated with simple PCI followed by dual antiplatelet therapy."

Journal • Acute Coronary Syndrome • Cardiovascular • Gastroenterology • Pain • Thrombosis

Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage. (PubMed, Blood Adv) - "This process was insensitive to blebbistatin, latrunculin A, and abciximab...Blood clot shrinkage can be caused by RBCs alone and this effect is due to the RBC aggregation driven mainly by osmotic depletion. The RBC-induced clot shrinkage may reinforce platelet-driven blood clot contraction and promote clot compaction when there are few and/or dysfunctional platelets."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study. (PubMed, BMJ Open) - "A significant proportion of patients experienced short-term MACE after primary PCI. While none of the assessed scores demonstrated significant predictive power, the GRACE score exhibited comparatively better predictive ability than the TIMI, PAMI and CADILLAC scores."

Adverse events • Journal • Observational data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Catheter-Directed Thrombolysis in the Management of Thrombotic Peripheral Artery Occlusions-Acute and Mid-Term Clinical Outcomes. (PubMed, J Clin Med) - "Multivariate logistic regression analysis identified age, abciximab and alprostadil usage, and lysis duration as predictors for SAEs and the use of abciximab as a predictor of reperfusion edema/compartment syndrome... CDT is an effective endovascular method for the treatment of thrombotic peripheral artery occlusions but is associated with a high complication rate. For SAEs in general and bleeding specifically, increasing age, alprostadil use, and lysis duration were independent risk factors."

Clinical data • Journal • Cardiovascular • Peripheral Arterial Disease

TRANSIENT ISCHEMIC ATTACK, SEIZURE, AND DEEP VENOUS THROMBOSIS COMPLICATING INADVERTENT INTRAVENOUS ADMINISTRATION OF RECOMBINANT THROMBIN (CHEST 2024) - "Her urine culture revealed Citrobacter freundii susceptible to Cefepime...Her symptoms abated completely alongwith normalization of D-Dimer over the next three days and she was transitioned to oral Apixaban uneventfully. She was discharged on an intramuscular ertapenem regimen for two weeks... Topical thrombin is an effective hemostatic agent at bedside, but should be used cautiously."

Cardiovascular • CNS Disorders • Diabetes • Epilepsy • Hematological Disorders • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Freeze-Dried Platelets Decrease Bleeding in Refractory Thrombocytopenic Patients with Hematological Malignancies (AABB 2024) - P2 | "FPH ability to generate thrombin was not affected by abciximab... 24 hours post-administration, approximately 60% of all FPH-treated patients achieved treatment success, while no patient achieved success in the control group. FPH contributed to decreased bleeding in patients with hematologic malignancies and platelet refractoriness."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Thrombocytopenia • Thrombosis

Role of Intracoronary Adrenaline in the Treatment of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention. (PubMed, Cureus) - "The medication groups used are purine nucleoside (adenosine), calcium channel blockers (verapamil, nicardipine), beta 2 receptor agonists (adrenaline, nitroprusside), fibrinolytic agents (streptokinase, tissue plasminogen activators), glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban). We present a case of a woman hospitalized in non-ST elevation myocardial infarction (NSTEMI) conditions. Generally, we initially use IC nitrate or IC adenosine to resolve the phenomenon, and when the no-reflow persists we use IC adrenaline because of its side effects mentioned above. Anyway, we believe that in specific cases of hypotension and bradycardia, the use of adrenaline as the first line of therapy should be considered."

Journal • Cardiovascular • Coronary Artery Disease • Hypotension • Myocardial Infarction • Pain

Retention of critical hemostatic functions of amotosalen-UVA Pathogen-Reduced Cryoprecipitated Fibrinogen Complex under variable shear flow rates (ISTH 2024) - "We observed no differences in the kinetics of platelet adhesion to immobilized CRYO-AHF, IFC and LIFC, under low shear flow (300 s-1). In contrast, a lower number of platelets adhered onto immobilized CFC at low shear due to absence of functional vWF. The central importance of IIb3/fibrinogen and GPIb-IX-V/vWF bonds in platelet interactions with CRYO-AHF, IFC, LIFC was confirmed by inhibition with abciximab and caplacizumab, respectively."

Hematological Disorders • Infectious Disease